BioSpace News Archive

Frazier announced the closing of a $419M fund aimed solely at the industry.

The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.

CryoPort handles the products for more than 172 of the more than 800 immunotherapy trials underway.

As part of a strategic restructuring, Proteostasis is laying off 13 members of its R&D workforce.

New data for the immunotherapy DARZALEX (daratumumab) and first-in-class BTK inhibitor IMBRUVICA (ibrutinib) are among eight oral presentations from Janssen Research & Development, LLC, to be featured at the 59th American Society of Hematology Annual Meeting & Exhibition taking place December 9-12, in Atlanta, GA.

Net product revenue in the third quarter of 2017 achieved record levels.

Double-digit EPS growth reflecting strong revenue growth and progress of Global Opex Initiative.

MilliporeSigma today announced the signing of a Memorandum of Understanding with Samsung BioLogics for a strategic alliance on biopharma manufacturing and biologics process development.

The trial is expected to commence during the first half of 2018.

Biohaven and its wholly owned subsidiary, Biohaven Pharma, today announced that the FDA has notified the Company that it may proceed with its clinical investigation of sublingual BHV-0223 as a potential treatment for patients with ALS.